Preemptive versus prophylactic protocol to prevent cytomegalovirus infection after renal transplantation: A meta-analysis and systematic review of randomized controlled trials

Transplant Infectious Disease

Volumn 13, Issue 6, 2011, Pages 622-632

  Zhang, L F ^a   Wang, Y T ^a   Tian, J H ^a   Yang, K H ^a   Wang, J Q ^a  

^a LANZHOU UNIVERSITY   (China)

Author keywords

CMV; Cytomegalovirus; Preemptive; Prophylaxis; Renal transplantation; Systematic review

Indexed keywords

GANCICLOVIR; VALACICLOVIR; VALGANCICLOVIR;

CLINICAL PROTOCOL; CYTOMEGALOVIRUS INFECTION; DRUG EFFICACY; DRUG SAFETY; HUMAN; INFECTION PREVENTION; KIDNEY TRANSPLANTATION; META ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECIPIENT; RECURRENCE RISK; REVIEW; RISK REDUCTION; SYSTEMATIC REVIEW;

ANTIVIRAL AGENTS; CHEMOPREVENTION; CYTOMEGALOVIRUS INFECTIONS; HUMANS; KIDNEY TRANSPLANTATION; POSTOPERATIVE COMPLICATIONS; TREATMENT OUTCOME;

EID: 84155181164     PISSN: 13982273     EISSN: 13993062     Source Type: Journal    
DOI: 10.1111/j.1399-3062.2011.00652.x     Document Type: Review

References (16)

1. Xu Y, Liang Y-B, Mao H-P, et al. Renal transplantation recipient's CMV infection and the affect of immunosuppressive agents. China J Organ Transplant 2001; 22: 201-203.
2. Sagedal S, Hartmann A, Nordal KP, et al. Impact of early cytomegalovirus infection and disease on long-term recipient and kidney graft survival. Kidney Int 2004; 66(1): 329-337.
3. Chen JS, Tang Zh. CMV infection in lung after renal transplantation. Ren Dis Dial Ren Transplant J 2003; 12: 397-400.
4. Paya CV. Prevention of cytomegalovirus disease in recipients of solid organ transplants. Clin Infect Dis 2001; 32(4): 596-603.
5. Strippoli GFM, Hodson EM, Jones CA, et al. Pre-emptive treatment for cytomegalovirus viraemia to prevent cytomegalovirus disease in solid organ transplant recipients. Cochrane Database Syst Rev 2006 10.1002/14651858.CD005133.pub2 (2006).
6. Tian X-H, Xue W-J, Ding X-M, et al. Preemptive therapy for prevention and treatment of cytomegalovirus disease after renal transplantation. J Fourth Mil Med Univ 2005; 26(18): 1695-1697.
7. Qiu J, Chen L-Z, Li J, et al. Prospective study of preemptive prophylaxis strategy combined with recipient' risk-factors to prevent CMV disease after kidney transplantation. China J Organ Transplant 2008; 29(5): 294-297.
8. Higgins JPT, Green S, eds. Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.1. Chichester, UK: The Cochrane Collaboration, 2008. Available at (Updated September 2008).
9. Higgins JPT, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. BMJ 2003; 327: 557-560.
10. Jung C, Engelmann E, Borner K, et al. Preemptive oral ganciclovir therapy versus prophylaxis to prevent symptomatic cytomegalovirus infection after kidney transplantation. Transplant Proc 2001; 33: 3621-3623.
11. Queiroga M, Castro MC, Araujo LM, et al. A prospective, randomized controlled trial comparing oral ganciclovir with weekly-monitored CMV antigenemia in renal transplant patients with a high-risk for CMV infection [abstract]. Am J Transplant 2003; 3(Suppl 5): 511. [CENTRAL: CN-00447308].
12. Khoury JA, Storch GA, Bohl DL, et al. Prophylactic versus preemptive oral valganciclovir for the management of cytomegalovirus infection in adult renal transplant recipients. Am J Transplant 2006; 6(9): 2134-2143.
13. Reischig T, Jindra P, Hes O, et al. Valacyclovir prophylaxis versus preemptive valganciclovir therapy to prevent cytomegalovirus disease after renal transplantation. Am J Transplant 2008; 8(1): 69-77.
14. Kliem V, Fricke L, Wollbrink T, et al. Improvement in long-term renal graft survival due to CMV prophylaxis with oral ganciclovir: results of a randomized clinical trial. Am J Transplant 2008; 8(5): 975-983.
15. Miller GG, Kaplan B. Prophylaxis versus preemptive protocols for CMV: do they impact graft survival? Am J Transplant 2008; 8: 913-914.
16. Baillie GM. Prevention of cytomegalovirus disease in solid organ transplant patients: prophylactic versus preemptive therapy. Am J Health Syst Pharm 2006; 63(19 Suppl 5): S10-S16.